Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its price objective decreased by SVB Securities from $976.00 to $895.00 in a research report issued to clients and investors on Friday, The Fly reports. SVB Securities’ price target points to a potential upside of 17.44% from the stock’s previous close. A number of other brokerages have also […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) Director Michael S. Brown sold 3,070 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, April 21st. The shares were sold at an average price of $798.42, for a total transaction of $2,451,149.40. Following the transaction, the director now owns 1,247 shares in the company, valued at […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) has earned an average rating of “Moderate Buy” from the twenty-six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $819.31, for a total value of $81,931.00. Following the completion of the transaction, the director now directly owns 19,047 […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its price objective lifted by JPMorgan Chase & Co. from $900.00 to $950.00 in a research report sent to investors on Friday morning, The Fly reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock. A number of other research firms also recently […]